| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 20% | $81,198,952 | 7,135,233 | Third Rock Ventures V, L.P. | 31 Dec 2024 | |||
| Cormorant Asset Management, LP | 6.4% | -5% | $82,045,819 | -$4,471,500 | 3,027,521 | -5.2% | Cormorant Asset Management, LP | 31 Dec 2025 |
| BlackRock, Inc. | 5% | $72,741,637 | 2,397,549 | BlackRock, Inc. | 31 Dec 2025 | |||
| Sofinnova Venture Partners XI, L.P. | 4.2% | $29,155,258 | 1,947,579 | Dr. James I. Healy ("Healy") | 11 Sep 2025 | |||
| JOHNSON & JOHNSON | 4.9% | $53,000,690 | 1,784,517 | JOHNSON & JOHNSON | 30 Sep 2025 |
As of 31 Dec 2025, 142 institutional investors reported holding 51,083,890 shares of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP). This represents 107% of the company’s total 47,677,496 outstanding shares.
The largest institutional shareholders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) together control 98% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TRV GP V, LLC | 15% | 7,135,233 | 0% | 50% | $216,482,969 |
| FMR LLC | 15% | 7,111,865 | +2.8% | 0.01% | $215,773,984 |
| ARCH Venture Management, LLC | 7.8% | 3,728,738 | 0% | 17% | $113,129,911 |
| Capital International Investors | 7.1% | 3,402,529 | 0% | 0.02% | $103,232,730 |
| Cormorant Asset Management, LP | 6.4% | 3,027,521 | -5.2% | 5.2% | $91,854,987 |
| GOLDMAN SACHS GROUP INC | 6.3% | 3,001,879 | +24% | 0.01% | $91,077,009 |
| BlackRock, Inc. | 5.1% | 2,431,862 | +55% | 0% | $73,782,693 |
| Sofinnova Investments, Inc. | 4% | 1,904,408 | -2.2% | 2.5% | $57,779,739 |
| VANGUARD GROUP INC | 3.8% | 1,817,757 | +12% | 0% | $55,150,747 |
| JOHNSON & JOHNSON | 3.7% | 1,784,517 | 0% | 9.8% | $54,142,246 |
| BAKER BROS. ADVISORS LP | 3.2% | 1,547,090 | 0% | 0.27% | $46,938,711 |
| Vestal Point Capital, LP | 2.3% | 1,110,000 | +17% | 1.2% | $33,677,400 |
| Polar Capital Holdings Plc | 2.1% | 1,004,728 | +7% | 0.14% | $30,483,448 |
| TRV GP VI, LLC | 2% | 969,218 | 0% | 20% | $29,406,074 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2% | 952,371 | +6.7% | 0.01% | $28,894,936 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 881,609 | -20% | 0% | $26,749,000 |
| ALLIANCEBERNSTEIN L.P. | 1.7% | 788,411 | -7.9% | 0.01% | $23,920,390 |
| STATE STREET CORP | 1.5% | 714,821 | +92% | 0% | $21,687,669 |
| Siren, L.L.C. | 1.5% | 708,469 | -33% | 0.64% | $21,494,949 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 694,734 | +30% | 0% | $21,081,433 |
| PERCEPTIVE ADVISORS LLC | 1.4% | 673,923 | +67% | 0.37% | $20,446,824 |
| T. Rowe Price Investment Management, Inc. | 1.3% | 619,029 | -13% | 0.01% | $18,782,000 |
| Invesco Ltd. | 0.56% | 267,120 | +69% | 0% | $8,104,422 |
| PRUDENTIAL FINANCIAL INC | 0.53% | 254,967 | 0.01% | $7,735,699 | |
| BURKEHILL GLOBAL MANAGEMENT, LP | 0.52% | 250,000 | 0% | 0.5% | $7,585,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 51,083,890 | $1,549,883,454 | +$54,540,100 | $30.34 | 142 |
| 2025 Q3 | 49,276,697 | $1,463,478,389 | +$335,895,056 | $29.70 | 123 |
| 2025 Q2 | 38,494,803 | $437,875,302 | +$4,896,059 | $11.37 | 81 |
| 2025 Q1 | 38,102,588 | $382,320,591 | +$11,241,443 | $10.03 | 77 |
| 2024 Q4 | 36,577,539 | $648,890,836 | -$29,671 | $17.74 | 69 |
| 2024 Q3 | 28,444,042 | $581,877,476 | +$37,552,009 | $20.48 | 55 |
| 2024 Q2 | 25,558,517 | $593,435,106 | +$593,435,106 | $23.26 | 35 |